Arava, Avandia's Divergent Paths: FDA Strengthens Arava Label Warning
This article was originally published in The Pink Sheet Daily
As FDA advisory committee debated the fate of Avandia, the agency bolsters liver warning on Arava, another drug David Graham suggested be removed from the market.
You may also be interested in...
Agency’s assessment of teriflunomide for multiple sclerosis incorporated the known safety data for leflunomide, a chemically related drug with an extensive post-marketing record in rheumatoid arthritis. Despite hepatotoxicity and other safety concerns with the older drug, its clinical experience provided reassurance that Aubagio’s risks could be managed without a REMS.
Two advisory panels recommended that FDA allow the trial of GlaxoSmithKline's Avandia (rosiglitazone) to continue but questioned its design, providing important hints for drug companies planning post-marketing safety trials in the future.
Company's internal e-mails suggest GSK hid vital studies related to safety of Avandia relative to competitor, senators charge.